INVIVYD, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
INVIVYD, INC. (IVVD) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 107.87 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-13
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 107.87M shares.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 107.55M shares.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 61.30M shares, a 3217.25% increase year-over-year.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 249.77K shares.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 42.62M shares.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 20.35M shares.
- INVIVYD, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 125.57K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 1 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 4 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 7 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2022-03-31 | 107.87M shares 10-Q · filed 2022-05-13 | 107.71M shares derived: average of 2 quarters · filed 2022-05-13 | 92.24M shares derived: average of 3 quarters · filed 2022-05-13 | 69.24M shares derived: average of 4 quarters · filed 2022-05-13 | |||
| 2021-12-31 | 107.55M shares 10-K · filed 2022-03-31 | 84.42M shares derived: average of 2 quarters · filed 2022-03-31 | 56.37M shares derived: average of 3 quarters · filed 2022-03-31 | 42.62M shares 10-K · filed 2022-03-31 | |||
| 2021-09-30 | 61.30M shares 10-K · filed 2022-03-31 | 30.77M shares derived: average of 2 quarters · filed 2022-03-31 | 20.35M shares 10-Q · filed 2021-11-15 | 20.35M shares 10-K · filed 2022-03-31 | |||
| 2021-06-30 | 249.77K shares 10-K · filed 2022-03-31 | 125.57K shares 10-Q · filed 2021-09-20 | 125.57K shares 10-K · filed 2022-03-31 | ||||
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | 3.61M shares 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 1.85M shares 10-Q · filed 2021-11-15 | 6.38M shares 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | 21.25M shares 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |